Balstilimab & Botensilimab insights with Dr Benjamin Schlechter - Latest MSS CRC Data from ESMO GI скачать в хорошем качестве

Balstilimab & Botensilimab insights with Dr Benjamin Schlechter - Latest MSS CRC Data from ESMO GI

In this exclusive OncoDaily interview, Amalya Sargsyan, Medical Oncologist and Head of Research & Intelligence of OncoDaily, welcomes Dr. Benjamin Schlechter from Dana-Farber Cancer Institute to discuss promising immunotherapy results for MSS colorectal cancer unveiled at ESMO GI 2025. Dr. Schlechter highlights data on the combination of a next-generation CTLA‑4 inhibitor (botensilimab) plus a PD‑1 inhibitor (balstilimab) in a heavily pretreated, microsatellite‑stable metastatic colorectal cancer (MSS mCRC) population without active liver metastases. Key points: ✅ Objective responses (~20%) in refractory MSS mCRC patients, a historically unresponsive group ✅ Durable benefit — median overall survival around 21 months, with a two‑year survival plateau ✅ Remains effective across multiple prior lines of therapy, including heavily pretreated and fourth‑line or later cohorts ✅ Manageable safety profile, with no new safety concerns reported ✅ This regimen may redefine treatment for MSS colorectal cancer—from “cold” to immunotherapy-responsive tumors. This detailed conversation sheds light on a potentially transformative approach in MSS colorectal cancer — offering new hope for patients with limited options. #ESMOGI2025 #OncoDaily #BenjaminSchlechter #MSSColorectalCancer #Immunotherapy #Botensilimab #Balstilimab #GIOncology #CancerResearch #OncologyInnovation SUBSCRIBE to get the latest #oncodaily    / @oncodailytv   Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn:   / oncodaily   Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram:   / oncodailynews   Follow OncoDaily on TikTok:   / oncodaily   Like OncoDaily on Facebook:   / oncodaily   SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/